Buprenorphine Treatment for Autonomic Dysfunction Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to accurately diagnose and treat autonomic dysfunction caused by opioid use and subsequent cessation or reduction, often misdiagnosing it as opioid addiction, leading to improper treatment with partial opioid agonists like buprenorphine.
Innovation Solution
Administering buprenorphine on a needed basis and monitoring patients periodically or in real-time to manage autonomic dysfunction, using methods such as heart rate variability and blood catecholamine concentration measurements to adjust treatment, and employing remote monitoring systems for ongoing patient assessment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If buprenorphine is administered to treat opioid addiction, then opioid withdrawal symptoms are reduced, but autonomic dysfunction symptoms worsen due to misdiagnosis
Solution Approach 1:
The patent inverts the conventional diagnostic approach by treating autonomic dysfunction symptoms (tachycardia, hypertension, hyperthermia) as the primary indication for buprenorphine administration, rather than waiting for a confirmed opioid addiction diagnosis. This reversal allows timely intervention before permanent autonomic damage occurs.
Solution Approach 2:
The patent implements preliminary monitoring of autonomic symptoms (heart rate, blood pressure, temperature) to detect dysfunction early, before initiating buprenorphine treatment. This preliminary detection enables preventive action to avoid severe complications like adrenal insufficiency.
2Measurement precision
If conventional diagnostic methods are used, then opioid addiction can be identified, but autonomic dysfunction is misdiagnosed leading to improper treatment
Solution Approach 1:
The patent implements continuous feedback monitoring of autonomic symptoms (heart rate variability, blood pressure, temperature) to distinguish autonomic dysfunction from opioid addiction. This feedback loop enables real-time diagnostic adjustment and appropriate treatment selection.
Solution Approach 2:
The patent introduces autonomic symptom monitoring as an intermediary diagnostic tool between patient presentation and final diagnosis. This intermediary assessment prevents misdiagnosis by objectively measuring autonomic function before confirming opioid addiction.
3Ease of operation
If buprenorphine is administered on a needed basis, then autonomic dysfunction symptoms are managed, but treatment complexity increases due to monitoring requirements
Solution Approach 1:
The patent employs automated monitoring systems that self-regulate treatment timing based on detected autonomic symptoms. The system automatically administers buprenorphine when symptoms exceed thresholds, reducing manual intervention complexity while maintaining flexible, symptom-based treatment.
Data Source
AI summary
A method of treatment of a patient suffering from autonomic dysfunction is described. The method of treatment can include the steps of initially evaluating the patient and administering buprenorphine to treat the patient, for example, daily. The patient undergoing such treatment is subjected to monitoring. The monitoring of the patient may be on a periodic basis, for example, a weekly basis, a daily basis, or on a real-time basis. Such monitoring may be through any one or combination of a plurality of bodily measurements that includes, for example, heart rate variability or blood catecholamine concentrations. Monitoring of the patient may also occur remotely. Methods are also described for determining whether the amount of buprenorphine provided to the patient may be tapered.